Clik here to view.
マイクローバ・ライフ・サイエンシズが微生物叢を手掛けるオーストラリア企業として初のISO15189認証をNATAから取得
豪ブリスベーン -（ビジネスワイヤ） — マイクローバは、当社の世界有数の微生物叢解析技術を適用して診断アプリケーションへの道を開き、糞便検体を分析するための次世代シーケンシング（NGS）ベースの新しいノンターゲットアッセイ法でISO15189認証を取得しました。...
View ArticleClik here to view.
PerkinElmer India Welcomes Everest Instruments as its Primary, In-Country...
DELHI, India PerkinElmer Inc., a global leader committed to innovating for a healthier world, is set to provide customers with even greater access to its extensive and innovative dairy testing...
View ArticleClik here to view.
Chunghwa Telecom, Thai National Telecom, The WhiteSpace and Delta Electronics...
TAIPEI, Taiwan National Telecom (NT), The WhiteSpace (The WSP), Delta Electronics (Thailand) PCL. and Chunghwa Telecom signed a Memorandum of Understanding (MOU) for collaboration in a 5G private...
View ArticleClik here to view.
Crystallographic Discoveries Bring New Clarity to Pharmaceutical Psilocybin...
MADISON, Wis. Breakthrough research has now revealed the true crystal forms of pharmaceutical psilocybin. A new study overcomes experimental challenges to solve the crystallographic puzzle and...
View ArticleClik here to view.
Fresenius Medical Care launches new mobile app to empower and engage nurses
HONG KONG Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced the launch of Carrie, a custom-built mobile app that...
View ArticleClik here to view.
Fresenius Medical Care Asia Pacific Receives Prestigious ACHS Global Quality...
HONG KONG Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, was presented with the prestigious Australian Council for Healthcare...
View ArticleClik here to view.
Chinese Enterprise By-Health Launches the World’s First Personalized...
ZHUHAI, China On December 19th, By-Health took the lead in launching the first personalized customized vitamin concept product at the conference of “Definition of Nutrition Intelligence”, which...
View ArticleClik here to view.
iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other...
TAIPEI, Taiwan iXensor Co., Ltd. (6734.TWO) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005223/en/ iXensor’s PixoTest COVID-19...
View ArticleClik here to view.
TandemAI Announces $25 Million Seed ＆ Pre-series A Financing Led by OrbiMed...
SUZHOU, China & SHANGHAI TandemAI today announced it has raised $25 million in Seed and pre-Series A financing to advance its proprietary computational platform and expansion of its wet lab...
View ArticleClik here to view.
Ligand’s Partner CStone Pharmaceuticals Receives Approval in China for...
EMERYVILLE, Calif. Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its partner CStone Pharmaceuticals (HKEX: 2616) has received approval from China’s National Medical...
View ArticleClik here to view.
Curia Unveils Comprehensive mRNA Solution
ALBANY, N.Y. Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today unveiled its messenger RNA (mRNA) solution, which includes discovery, process...
View ArticleClik here to view.
Xlear提交对政府诉讼的法律回应
盐湖城 (美国商业资讯)–今天，Xlear Inc.提交公司对美国司法部诉讼的回应，该诉讼指控公司违反《联邦贸易委员会法案》等。公司否认政府的所有指控，并针对政府提出一系列积极抗辩，包括其侵犯Xlear根据《第一修正案》所拥有的言论自由权。Xlear首席执行官Nathan Jones就Xlear的回应发表如下陈述：...
View ArticleClik here to view.
DESTINY-Lung04 Phase 3 Trial of ENHERTU® Initiated in Patients with...
TOKYO & MUNICH & BASKING RIDGE, N.J. Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial...
View ArticleClik here to view.
Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1...
BROOKLYN, N.Y. Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced that the U.S. Food and Drug Administration...
View ArticleClik here to view.
Clik here to view.
Accutar Biotechnology、前立腺がんを対象としたAC0176の第1相臨床試験のIND申請をFDAが承認したと発表
米ニューヨーク州ブルックリン （ビジネスワイヤ） — 人工知能（AI）の力を活用した創薬に傾注するバイオテクノロジー企業のAccutar Biotechnology,...
View ArticleClik here to view.
Accutar Biotechnology宣布FDA批准AC0176用于治疗前列腺癌的1期试验的IND申请
纽约布鲁克林 (美国商业资讯)–专注于利用人工智能(AI)赋能药物发现的生物技术公司Accutar Biotechnology, Inc.今天宣布，美国食品药品管理局(FDA)已批准该公司在研新药AC0176用于治疗转移性去势难治性前列腺癌(mCRPC)患者的试验用新药申请(IND)。AC0176是一种口服生物可利用(orally...
View ArticleClik here to view.
Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics...
View ArticleClik here to view.
CORRECTING and REPLACING Chinese Enterprise By-Health Launches the First...
ZHUHAI, China Please replace the release dated December 22, 2021 with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here:...
View ArticleClik here to view.
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and...
BALTIMORE MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment...
View Article